204 related articles for article (PubMed ID: 25262581)
1. Targeted antitumor efficacy and imaging via multifunctional nano-carrier conjugated with anti-HER2 trastuzumab.
Choi WI; Lee JH; Kim JY; Heo SU; Jeong YY; Kim YH; Tae G
Nanomedicine; 2015 Feb; 11(2):359-68. PubMed ID: 25262581
[TBL] [Abstract][Full Text] [Related]
2. Triple Therapy of HER2
Zolata H; Afarideh H; Davani FA
Cancer Biother Radiopharm; 2016 Nov; 31(9):324-329. PubMed ID: 27831759
[TBL] [Abstract][Full Text] [Related]
3. The effect of mechanical properties of iron oxide nanoparticle-loaded functional nano-carrier on tumor targeting and imaging.
Choi WI; Kim JY; Heo SU; Jeong YY; Kim YH; Tae G
J Control Release; 2012 Sep; 162(2):267-75. PubMed ID: 22824783
[TBL] [Abstract][Full Text] [Related]
4. Intracellular routing in breast cancer cells of streptavidin-conjugated trastuzumab Fab fragments linked to biotinylated doxorubicin-functionalized metal chelating polymers.
Liu P; Cai Z; Kang JW; Boyle AJ; Adams J; Lu Y; Ngo Ndjock Mbong G; Sidhu S; Reilly RM; Winnik MA
Biomacromolecules; 2014 Mar; 15(3):715-25. PubMed ID: 24506198
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab.
Yousefpour P; Atyabi F; Vasheghani-Farahani E; Movahedi AA; Dinarvand R
Int J Nanomedicine; 2011; 6():1977-90. PubMed ID: 21976974
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab modified silica nanoparticles loaded with doxorubicin for targeted and synergic therapy of breast cancer.
Meng LX; Ren Q; Meng Q; Zheng YX; He ML; Sun SY; Ding ZJ; Li BC; Wang HY
Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S556-S563. PubMed ID: 30146920
[TBL] [Abstract][Full Text] [Related]
7. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
8. Theranostic pH-sensitive nanoparticles for highly efficient targeted delivery of doxorubicin for breast tumor treatment.
Pan C; Liu Y; Zhou M; Wang W; Shi M; Xing M; Liao W
Int J Nanomedicine; 2018; 13():1119-1137. PubMed ID: 29520140
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab-conjugated liposome-coated fluorescent magnetic nanoparticles to target breast cancer.
Jang M; Yoon YI; Kwon YS; Yoon TJ; Lee HJ; Hwang SI; Yun BL; Kim SM
Korean J Radiol; 2014; 15(4):411-22. PubMed ID: 25053899
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of cancer therapy efficacy by trastuzumab-conjugated and pH-sensitive nanocapsules with the simultaneous encapsulation of hydrophilic and hydrophobic compounds.
Chiang CS; Hu SH; Liao BJ; Chang YC; Chen SY
Nanomedicine; 2014 Jan; 10(1):99-107. PubMed ID: 23891983
[TBL] [Abstract][Full Text] [Related]
11. IONP-doped nanoparticles for highly effective NIR-controlled drug release and combination tumor therapy.
Fu X; Wang X; Zhou S; Zhang Y
Int J Nanomedicine; 2017; 12():3751-3766. PubMed ID: 28553112
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab-Coated Thermo-Sensitive Liposomes Loaded with Magnetic Nanoparticles and Doxorubicin for Targeted EGFR-Expressing Breast Cancer Combined Therapy.
Dorjsuren B; Chaurasiya B; Ye Z; Liu Y; Li W; Wang C; Shi D; Evans CE; Webster TJ; Shen Y
Int J Nanomedicine; 2020; 15():8201-8215. PubMed ID: 33122906
[TBL] [Abstract][Full Text] [Related]
13. Tumor targeting using anti-her2 immunoliposomes.
Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
[TBL] [Abstract][Full Text] [Related]
14. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.
Gianolio DA; Rouleau C; Bauta WE; Lovett D; Cantrell WR; Recio A; Wolstenholme-Hogg P; Busch M; Pan P; Stefano JE; Kramer HM; Goebel J; Krumbholz RD; Roth S; Schmid SM; Teicher BA
Cancer Chemother Pharmacol; 2012 Sep; 70(3):439-49. PubMed ID: 22821053
[TBL] [Abstract][Full Text] [Related]
15. Her2-Targeted Multifunctional Nano-Theranostic Platform Mediates Tumor Microenvironment Remodeling and Immune Activation for Breast Cancer Treatment.
Zheng D; Wan C; Yang H; Xu L; Dong Q; Du C; Du J; Li F
Int J Nanomedicine; 2020; 15():10007-10028. PubMed ID: 33376321
[TBL] [Abstract][Full Text] [Related]
16. Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI.
Chen TJ; Cheng TH; Chen CY; Hsu SC; Cheng TL; Liu GC; Wang YM
J Biol Inorg Chem; 2009 Feb; 14(2):253-60. PubMed ID: 18975017
[TBL] [Abstract][Full Text] [Related]
17. Functionalized magnetic dextran-spermine nanocarriers for targeted delivery of doxorubicin to breast cancer cells.
Tarvirdipour S; Vasheghani-Farahani E; Soleimani M; Bardania H
Int J Pharm; 2016 Mar; 501(1-2):331-41. PubMed ID: 26875475
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, characterization and theranostic evaluation of Indium-111 labeled multifunctional superparamagnetic iron oxide nanoparticles.
Zolata H; Abbasi Davani F; Afarideh H
Nucl Med Biol; 2015 Feb; 42(2):164-70. PubMed ID: 25311750
[TBL] [Abstract][Full Text] [Related]
19. Functionalized nanoscale β-1,3-glucan to improve Her2+ breast cancer therapy: In vitro and in vivo study.
Nasrollahi Z; Mohammadi SR; Mollarazi E; Yadegari MH; Hassan ZM; Talaei F; Dinarvand R; Akbari H; Atyabi F
J Control Release; 2015 Mar; 202():49-56. PubMed ID: 25597638
[TBL] [Abstract][Full Text] [Related]
20. Targeted doxorubicin delivery and release within breast cancer environment using PEGylated chitosan nanoparticles labeled with monoclonal antibodies.
Helmi O; Elshishiny F; Mamdouh W
Int J Biol Macromol; 2021 Aug; 184():325-338. PubMed ID: 34119547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
